BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rovatti PE, Gambacorta V, Lorentino F, Ciceri F, Vago L. Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation. Front Immunol 2020;11:147. [PMID: 32158444 DOI: 10.3389/fimmu.2020.00147] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Muñiz P, Kwon M, Carbonell D, Chicano M, Bailén R, Oarbeascoa G, Suárez-González J, Andrés-Zayas C, Menárguez J, Dorado N, Gómez-Centurión I, Anguita J, Díez-Martín JL, Martínez-Laperche C, Buño I. Clinical Utility of the Detection of the Loss of the Mismatched HLA in Relapsed Hematological Patients After Haploidentical Stem Cell Transplantation With High-Dose Cyclophosphamide. Front Immunol 2021;12:642087. [PMID: 33841425 DOI: 10.3389/fimmu.2021.642087] [Reference Citation Analysis]
2 Shah RM. Contemporary haploidentical stem cell transplant strategies in children with hematological malignancies. Bone Marrow Transplant 2021;56:1518-34. [PMID: 33674791 DOI: 10.1038/s41409-021-01246-5] [Reference Citation Analysis]
3 Blouin AG, Ye F, Williams J, Askar M. A practical guide to chimerism analysis: Review of the literature and testing practices worldwide. Hum Immunol 2021;82:838-49. [PMID: 34404545 DOI: 10.1016/j.humimm.2021.07.013] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ab Rahman S, Matic T, Yordanova M, Ariffin H. HLA-Haploidentical Family Donors: The New Promise for Childhood Acute Lymphoblastic Leukaemia? Front Pediatr 2022;9:758680. [DOI: 10.3389/fped.2021.758680] [Reference Citation Analysis]
5 Gonzalez-vicent M, Molina B, Lopez I, Zubicaray J, Ruiz J, Vicario JL, Sebastián E, Iriondo J, Castillo A, Abad L, Ramirez M, Sevilla J, Diaz MA. T-Cell Depleted Haploidentical Transplantation in Children With Hematological Malignancies: A Comparison Between CD3+/CD19+ and TCRαβ+/CD19+ Depletion Platforms. Front Oncol 2022;12:884397. [DOI: 10.3389/fonc.2022.884397] [Reference Citation Analysis]
6 Shyr DC, Zhang BM, Saini G, Madani ND, Schultz LM, Patel S, Kristovich K, Fernandez-Vina M, Bertaina A. HLA-haplotype loss after TCRαβ/CD19-depleted haploidentical HSCT. Bone Marrow Transplant 2021;56:733-7. [PMID: 33070150 DOI: 10.1038/s41409-020-01081-0] [Reference Citation Analysis]
7 Zhou W, Xu S, Deng T, Zhou R, Wang C. LncRNA USP30-AS1 promotes the survival of acute myeloid leukemia cells by cis-regulating USP30 and ANKRD13A. Hum Cell 2021. [PMID: 34694569 DOI: 10.1007/s13577-021-00636-7] [Reference Citation Analysis]
8 Wu HW, Zhao YM, Huang H. [Mechanism of relapse and its therapeutic strategies after allogeneic hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi 2021;42:869-77. [PMID: 34788930 DOI: 10.3760/cma.j.issn.0253-2727.2021.10.014] [Reference Citation Analysis]
9 Kunadt D, Stölzel F. Effective Immunosurveillance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. Cancer Manag Res 2021;13:7411-27. [PMID: 34594134 DOI: 10.2147/CMAR.S261721] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Ciciarello M, Corradi G, Forte D, Cavo M, Curti A. Emerging Bone Marrow Microenvironment-Driven Mechanisms of Drug Resistance in Acute Myeloid Leukemia: Tangle or Chance? Cancers (Basel) 2021;13:5319. [PMID: 34771483 DOI: 10.3390/cancers13215319] [Reference Citation Analysis]
11 Salhotra A, Stein AS. Role of Radiation Based Conditioning Regimens in Patients With High-Risk AML Undergoing Allogenic Transplantation in Remission or Active Disease and Mechanisms of Post-Transplant Relapse. Front Oncol 2022;12:802648. [PMID: 35242706 DOI: 10.3389/fonc.2022.802648] [Reference Citation Analysis]
12 Adachi Y, Sakai T, Terakura S, Shiina T, Suzuki S, Hamana H, Kishi H, Sasazuki T, Arase H, Hanajiri R, Goto T, Nishida T, Murata M, Kiyoi H. Downregulation of HLA class II is associated with relapse after allogeneic stem cell transplantation and alters recognition by antigen-specific T cells. Int J Hematol 2022. [PMID: 35037229 DOI: 10.1007/s12185-021-03273-w] [Reference Citation Analysis]
13 Huschart E, Miller H, Salzberg D, Campbell C, Beebe K, Schwalbach C, Magee K, Adams RH, Ngwube A. Azacitidine and prophylactic donor lymphocyte infusions after hematopoietic stem cell transplantation for pediatric high-risk acute myeloid leukemia. Pediatr Hematol Oncol 2021;38:154-60. [PMID: 33150833 DOI: 10.1080/08880018.2020.1829220] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Greco R, Lorentino F, Albanese S, Lupo Stanghellini MT, Giglio F, Piemontese S, Clerici D, Lazzari L, Marcatti M, Mastaglio S, Xue E, Farina F, Pavesi F, Assanelli A, Carrabba MG, Marktel S, Vago L, Bonini C, Corti C, Bernardi M, Ciceri F, Peccatori J. Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant. Transplant Cell Ther 2021;27:776.e1-776.e13. [PMID: 34087452 DOI: 10.1016/j.jtct.2021.05.023] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
15 Rozmus J, Bhatt ST, Buxbaum NP, Cuvelier GDE, Li AM, Kitko CL, Schultz KR. Is It Possible to Separate the Graft-Versus-Leukemia (GVL) Effect Against B Cell Acute Lymphoblastic Leukemia From Graft-Versus-Host Disease (GVHD) After Hematopoietic Cell Transplant? Front Pediatr 2022;10:796994. [DOI: 10.3389/fped.2022.796994] [Reference Citation Analysis]
16 Barros MS, de Araújo ND, Magalhães-Gama F, Pereira Ribeiro TL, Alves Hanna FS, Tarragô AM, Malheiro A, Costa AG. γδ T Cells for Leukemia Immunotherapy: New and Expanding Trends. Front Immunol 2021;12:729085. [PMID: 34630403 DOI: 10.3389/fimmu.2021.729085] [Reference Citation Analysis]